The economics of TB control in developing countries

被引:11
作者
Walker, D
Stevens, W
机构
[1] Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England
[2] MRC Labs, Banjul, Gambia
基金
英国医学研究理事会;
关键词
control; cost-effectiveness analysis; costs; developing countries; economics; tuberculosis;
D O I
10.1517/14656566.4.3.359
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tuberculosis is one of the world's biggest killers and the burden is skewed towards developing countries, where the relative share of this disease is largest. This has much to do with poor living conditions and less developed public health systems. Nevertheless, even with these factors taken into account, the mortality from this disease is still unjustifiably high given the fact that it is treatable in the vast majority of cases with relatively inexpensive drugs. There are three main reasons for this situation: a low propensity to seek healthcare when sick, poor diagnosis upon seeking care, and high levels of non-compliance with treatment when diagnosed. Taken in combination, this means that of those who seek care, some get appropriate diagnosis at their first contact, while many do not. Unfortunately, not all of those who are diagnosed actually begin treatment and of those who do, a smaller percentage actually complete it. This article will look at each of these issues, and in particular their costs, in turn, and suggest areas in which economics can help to develop solutions to them.
引用
收藏
页码:359 / 368
页数:10
相关论文
共 55 条
[1]  
AHLBURG DA, 2000, EC IMPACTS TUBERCULS
[2]   A 4 STUDY OF CASE-FINDING METHODS FOR PULMONARY TUBERCULOSIS IN KENYA [J].
ALUOCH, JA ;
EDWARDS, EA ;
STOTT, H ;
FOX, W ;
SUTHERLAND, I .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1982, 76 (05) :679-691
[3]  
[Anonymous], 2001, EC TB DRUG DEV
[4]   DELAY IN THE DIAGNOSIS, NOTIFICATION AND INITIATION OF TREATMENT AND COMPLIANCE IN CHILDREN WITH TUBERCULOSIS [J].
BEYERS, N ;
GIE, RP ;
SCHAAF, HS ;
VANZYL, S ;
NEL, ED ;
TALENT, JM ;
DONALD, PR .
TUBERCLE AND LUNG DISEASE, 1994, 75 (04) :260-265
[5]  
Bishai DM, 2001, INT J TUBERC LUNG D, V5, P984
[6]  
BRISSONNOEL A, 1989, LANCET, V2, P1069
[7]   COST-EFFECTIVENESS OF ANTITUBERCULOSIS INTERVENTIONS [J].
CASTELO, A ;
MATHIASI, PA ;
IUNES, R ;
KRITSKI, AL ;
DALCOLMO, M ;
DEMELO, FF ;
DRUMMOND, M .
PHARMACOECONOMICS, 1995, 8 (05) :385-399
[8]   The global tuberculosis situation - Progress and problems in the 20th century, prospects for the 21st century [J].
Cegielski, JP ;
Chin, DP ;
Espinal, MA ;
Frieden, TR ;
Cruz, RR ;
Talbot, EA ;
Weil, DEC ;
Zaleskis, R ;
Raviglione, MC .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2002, 16 (01) :1-+
[9]   TUBERCULOSIS-CONTROL IN RESOURCE-POOR COUNTRIES - ALTERNATIVE APPROACHES IN THE ERA OF HIV [J].
DECOCK, KM ;
WILKINSON, D .
LANCET, 1995, 346 (8976) :675-677
[10]   Global burden of tuberculosis - Estimated incidence, prevalence, and mortality by country [J].
Dye, C ;
Scheele, S ;
Dolin, P ;
Pathania, V ;
Raviglione, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :677-686